NCT06121271View on ClinicalTrials.gov

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

November 6, 2027

Study Completion Date

November 6, 2027

Conditions
Bronchial and Thymic Neuroendocrine TumourParaganglioma/ PhaeochromocytomaMedullary Thyroid CarcinomaThose Requiring Repeat Peptide Receptor Radionuclide Therapy
Interventions
DRUG

Lu-177 DOTATATE (Lutathera®)

Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.

All Listed Sponsors
lead

University College, London

OTHER